癌症新生抗原：增强免疫疗法。
Cancer neoantigen: Boosting immunotherapy.
机构信息
Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, 524023, China; The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, 524023, China; The Key Lab of Zhanjiang for R&D Marine Microbial Resources in the Beibu Gulf Rim, Guangdong Medical University, Zhanjiang, 524023, China.
Cancer Center, Affiliated Hospital, Guangdong Medical University, Zhanjiang, 524023, China.
出版信息
Biomed Pharmacother. 2020 Nov;131:110640. doi: 10.1016/j.biopha.2020.110640. Epub 2020 Aug 21.
Tumor neoantigen has a high degree of immunogenicity. As one of the emerging methods of tumor immunotherapy, the vaccine developed against it has served to clinical trials of various solid tumors, especially in the treatment of melanoma. Currently, a variety of immunotherapy methods have been applied to the treatment of the tumor. However, other therapeutic methods have the disadvantages of low specificity and prominent side effects. Treatments require tumor antigen with higher immunogenicity as the target of immune attack. This review will recommend the identification of neoantigen, the influencing factors of neoantigen, and the application of personalized vaccines for neoantigen in metastatic tumors such as malignant melanoma.
肿瘤新生抗原具有高度的免疫原性。作为肿瘤免疫治疗的新兴方法之一，针对其开发的疫苗已应用于各种实体瘤的临床试验，尤其是在黑色素瘤的治疗中。目前，多种免疫治疗方法已应用于肿瘤的治疗。然而，其他治疗方法存在特异性低、副作用突出等缺点。治疗需要以具有更高免疫原性的肿瘤抗原作为免疫攻击的靶点。本综述将推荐鉴定新生抗原、影响新生抗原的因素，以及在转移性肿瘤（如恶性黑色素瘤）中应用个性化疫苗的相关内容。
Zotero 插件